Health Catalyst, Inc. (NASDAQ:HCAT) Insider Linda Llewelyn Sells 1,860 Shares

Health Catalyst, Inc. (NASDAQ:HCATGet Rating) insider Linda Llewelyn sold 1,860 shares of Health Catalyst stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $15.87, for a total value of $29,518.20. Following the completion of the sale, the insider now owns 60,173 shares in the company, valued at $954,945.51. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Linda Llewelyn also recently made the following trade(s):

  • On Monday, April 18th, Linda Llewelyn sold 2,039 shares of Health Catalyst stock. The stock was sold at an average price of $22.58, for a total value of $46,040.62.
  • On Tuesday, March 15th, Linda Llewelyn sold 2,039 shares of Health Catalyst stock. The stock was sold at an average price of $21.08, for a total value of $42,982.12.
  • On Thursday, March 3rd, Linda Llewelyn sold 218 shares of Health Catalyst stock. The stock was sold at an average price of $26.89, for a total value of $5,862.02.

Shares of NASDAQ HCAT opened at $14.02 on Thursday. The firm has a market cap of $759.74 million, a price-to-earnings ratio of -4.52 and a beta of 1.18. Health Catalyst, Inc. has a 52-week low of $12.33 and a 52-week high of $59.50. The business’s 50 day moving average is $21.20 and its two-hundred day moving average is $31.09.

Health Catalyst (NASDAQ:HCATGet Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. The company had revenue of $68.09 million for the quarter, compared to analyst estimates of $66.01 million. Health Catalyst had a negative return on equity of 19.88% and a negative net margin of 57.95%. The firm’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.37) earnings per share. On average, analysts predict that Health Catalyst, Inc. will post -1.8 EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. SVB Leerink lowered their target price on Health Catalyst from $64.00 to $48.00 and set an “outperform” rating on the stock in a report on Wednesday, March 2nd. Guggenheim assumed coverage on Health Catalyst in a report on Wednesday, April 13th. They set a “buy” rating and a $39.00 target price on the stock. Canaccord Genuity Group lowered their target price on Health Catalyst from $35.00 to $17.00 in a report on Wednesday, May 11th. BTIG Research reduced their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. Finally, Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $62.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, March 2nd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $34.85.

Several institutional investors have recently bought and sold shares of HCAT. Advisor Group Holdings Inc. increased its position in shares of Health Catalyst by 27.3% during the third quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock worth $73,000 after acquiring an additional 314 shares during the period. Swiss National Bank increased its position in shares of Health Catalyst by 1.5% during the third quarter. Swiss National Bank now owns 83,700 shares of the company’s stock worth $4,186,000 after acquiring an additional 1,200 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of Health Catalyst by 3.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 13,525 shares of the company’s stock worth $676,000 after acquiring an additional 480 shares during the period. Principal Financial Group Inc. increased its position in shares of Health Catalyst by 1.1% during the third quarter. Principal Financial Group Inc. now owns 114,630 shares of the company’s stock worth $5,733,000 after acquiring an additional 1,259 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Health Catalyst by 3.5% during the third quarter. BlackRock Inc. now owns 4,676,181 shares of the company’s stock worth $233,855,000 after purchasing an additional 156,525 shares in the last quarter. 97.53% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Further Reading

Insider Buying and Selling by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.